As a new-type foreign trade service provider driven by technological transformation and foreign trade business, HiSiaddi has established a "1+2+3+4=1" service system, and can supply Fmoc-8-amino-3,6-dioxaoctanoic acid (Semaglutide side chain intermediate) sourced from multiple well-known original manufacturers.
As a research-and-development-oriented foreign trade enterprise, HiSiaddi has conducted multiple rounds of on-site inspections of manufacturers producing Fmoc-8-amino-3,6-dioxaoctanoic acid (Semaglutide side chain intermediate) through technological transformation cooperation with manufacturers, possessing objective and in-depth understanding of different brands. Therefore, we regularly analyze various manufacturers of this intermediate for clients to assist them in selecting matching products. Below is the brand recommendation case.
For inquiries regarding multi-brand and model comparative analysis, please contact HiSiaddi customer service.
The client is Germany Peptide GmbH, a high-end biopharmaceutical enterprise headquartered in Munich, Germany, specializing in R&D and commercialization of long-acting GLP-1 innovative peptide drugs, supplying high-end medical markets in Germany, Switzerland, Austria and other European countries, and following strict FDA, EMA and ICH Q7 standards with extremely high requirements for intermediate brand compliance, batch consistency and technical service capacity. The annual procurement volume of Fmoc-8-amino-3,6-dioxaoctanoic acid (Semaglutide side chain intermediate) for solid-phase peptide synthesis mass production lines reaches 150kg, representing a high-end pharmaceutical-grade procurement scenario.
This is the client’s first procurement of this intermediate from China, lacking systematic knowledge of well-known domestic brands, technical echelons and mainstream product models. The 5 manufacturers contacted only promoted their own products while avoiding introduction of peer advantages, preventing the client from conducting horizontal comparisons and making informed decisions, with concerns that improper brand selection would disrupt production line stability and pharmaceutical compliance. The client entrusted HiSiaddi with multi-brand objective evaluation and targeted model selection services.
Combining industry reputation, production capacity scale, compliance qualifications and export experience, HiSiaddi screened 5 mainstream domestic brands focusing on peptide intermediates, all holding GMP certifications, with FDA/EMA audit experience and large-scale production capacity, covering three tiers: high-end, mid-to-high-end and conventional grade:
1. Sinopep Biotech (Brand: SN Bio): Domestic leader in GLP-1 intermediates, core global supplier of Semaglutide intermediates, high-end tier;
2. Nuota Biotech (Brand: Nuota): Expert in long-chain peptide manufacturing with ton-scale production capacity and FDA certification, high-end tier;
3. Kaimanni (Brand: Kaimanni): Specializes in Fmoc-protected amino acids and side chain intermediates with years of export experience to Europe, mid-to-high-end tier;
4. J&K Scientific (Brand: J&K): Supplier of high-end reagents and intermediates with strong R&D capacity, mid-to-high-end tier;
5. Dexin Zhiyuan Shanghai (Brand: Dexin): Supplier of conventional industrial-grade intermediates with obvious price advantages, conventional tier.
HiSiaddi conducted in-depth decomposition of mainstream models of the 5 brands across 7 dimensions: purity grade, impurity control, crystal form/particle size, compliance documentation, production capacity & lead time, price range and technical service, objectively presenting respective strengths and weaknesses.
Core Specifications: HPLC purity ≥99.8%, single impurity ≤0.04%, water content ≤80ppm, particle size D50=85±5μm, white high-crystallinity powder; Advantages: Industry-leading purity and impurity control meeting the highest EMA/FDA standards; stable crystal form with excellent dissolution performance; full set of English compliance documents (including method validation and stability data); customizable particle size and packaging; Disadvantages: Highest price (approx. RMB 1,800/kg); minimum order quantity of 5kg with lead time 15–20 days; Applicable Scenarios: Mass production lines of high-end pharmaceutical enterprises, projects subject to stringent EMA/FDA audits.
Core Specifications: HPLC purity ≥99.7%, single impurity ≤0.05%, water content ≤100ppm, particle size D50=90±10μm, white crystalline powder; Advantages: Strong batch consistency with ton-scale production capacity guaranteeing stable supply; passed FDA on-site audits with complete compliance documents; price 15% lower than Sinopep (approx. RMB 1,530/kg); lead time 12–15 days; Disadvantages: Slightly lower precision in particle size regulation compared with Sinopep; low priority for small-batch orders (<3kg); Applicable Scenarios: Mass production of mid-to-high-end pharmaceutical enterprises, long-term stable supply projects.
Core Specifications:
· Model 007: Purity ≥99.5%, single impurity ≤0.08%, water content ≤120ppm;
· Model 008: Purity ≥99.7%, single impurity ≤0.05%, water content ≤100ppm, customizable particle size; Advantages: Outstanding cost performance; Model 007 priced at approx. RMB 1,200/kg, Model 008 at approx. RMB 1,450/kg; 5 years of deep cultivation in European markets with full EMA regulation awareness; flexible small-batch production starting at 1kg with lead time 7–10 days; rapid technical response and capability to optimize dissolution and crystallization processes quickly; Disadvantages: Limited production capacity for high-end Model 008; full audit documents require advance application; Applicable Scenarios: R&D and small-batch mass production of mid-to-high-end pharmaceutical enterprises, cost-sensitive compliance projects.
Core Specifications: Purity ≥99.5%, single impurity ≤0.10%, water content ≤150ppm, broad particle size distribution (D50=70–110μm); Advantages: Strong R&D capacity with rapid new product iteration; reagent-grade quality with limited impurity species; abundant spot inventory ranging from 100g to 500g with lead time 3–5 days; Disadvantages: Insufficient mass production stability with large inter-batch particle size fluctuations; relatively high price (approx. RMB 1,350/kg); basic compliance documents lacking full validation reports; Applicable Scenarios: Lab-scale R&D and process exploration, unsuitable for large-scale mass production.
Core Specifications: Purity ≥99.0%, single impurity ≤0.20%, water content ≤200ppm, industrial-grade powder; Advantages: Lowest price (approx. RMB 800/kg); abundant spot inventory with short lead time; Disadvantages: Loose impurity control without internal testing for heavy metals and residual solvents; no GMP certification and inability to provide European & American compliance documents; poor crystal form prone to agglomeration during dissolution; Applicable Scenarios: Non-pharmaceutical-grade low-end industrial synthesis, completely inapplicable for high-end pharmaceutical enterprises.
Combining the client’s four core demands of EMA compliance, stable mass production, cost control and technical compatibility, HiSiaddi eliminated high-priced top-tier Sinopep, low-quality conventional Dexin and J&K with unstable mass production capacity, finally recommending 2 mid-to-high-end brands and 3 models covering full scenarios of "core mass production + flexible supplementary orders + R&D verification".
1.
Primary Recommended Brand: Nuota Biotech (Nuota) – Model: Nuota-Fmoc-168 (Core Mass Production) Recommendation Rationale: Purity of 99.7% and single impurity ≤0.05% fully meet the client’s EMA standards; ton-scale production capacity covers annual demand of 150kg with strong batch consistency; complete compliance documents certified by FDA directly usable for audits; 15% cost reduction versus top-tier brands with optimal cost performance; lead time of 12–15 days matching mass production rhythm.
2.
3.
Alternative Brand: Kaimanni (Kaimanni) with Dual Model Matching
4.
· Model 1: KMN-Fmoc-008 (Custom Grade, Flexible Supplementary Orders) Recommendation Rationale: Purity of 99.7% and single impurity ≤0.05% equivalent to Nuota; supports customization of small batches starting at 1kg with adjustable particle size matching client production lines; 7–10 day lead time for rapid supplementary supply; 5% lower price than Nuota for better cost control.
· Model 2: KMN-Fmoc-007 (Pharmaceutical Grade, R&D Verification) Recommendation Rationale: Purity of 99.5% satisfying quality control requirements for R&D stages; low price (RMB 1,200/kg) suitable for lab trials and process optimization; rapid technical response to support dissolution and coupling process debugging for clients.
1.
Client Decision-Making The client recognized HiSiaddi’s objective, data-driven evaluation logic and adopted the recommended solution: Nuota Nuota-Fmoc-168 for core mass production (annual procurement of 120kg), Kaimanni KMN-Fmoc-008 for flexible supplementary orders (annual procurement of 30kg), and KMN-Fmoc-007 reserved for R&D verification.
2.
3.
Procurement Implementation Results
4.
· Qualified Product Quality: After arrival of the first batch of 50kg Nuota material and 20kg Kaimanni material, client testing showed purities of 99.72% and 99.75% respectively, with single impurities all ≤0.04%, particle sizes matching production lines and uniform dissolution without agglomeration;
· Passed Compliance Audit: Full set of English COAs, spectra and validation reports passed internal client audit at one go, directly applicable for EMA quarterly audits;
· Optimized Costs: Overall procurement costs reduced by 18% compared with the original plan to purchase top-tier high-end brands;
· Stable Supply: Nuota guaranteed stable monthly supply of 10kg, while Kaimanni delivered supplementary orders within 7 days, fully matching the client’s production rhythm.
1. Client Feedback The client’s procurement director commented: “HiSiaddi breaks the information barrier created by manufacturers’ biased self-promotion, clarifies the true strength of domestic mid-to-high-end brands with objective data, and recommends models precisely matching our compliance, mass production and cost demands, eliminating model selection risks. It is a professional and trustworthy partner.”
A two-year long-term supply agreement was signed between both parties, and the client entrusted HiSiaddi with brand selection and procurement management for 3 additional newly added GLP-1 side chain intermediates.
When overseas mid-to-high-end pharmaceutical enterprises purchase Fmoc-8-amino-3,6-dioxaoctanoic acid, core pain points include asymmetric brand information, biased manufacturer promotion and difficulties in model selection decision-making. Domestic brands form clear tiers: high-end (Sinopep), mid-to-high-end (Nuota, Kaimanni, J&K) and conventional (Dexin), with significant gaps among different brands in purity, impurity control, compliance, production capacity and pricing.
HiSiaddi’s core value lies in independent third-party objective evaluation, unbound to any manufacturers. Starting from clients’ core demands, it conducts horizontal comparison of advantages and disadvantages across multiple brands to accurately screen mid-to-high-end brands and models with qualified quality, regulatory compatibility, controllable costs and stable supply. It avoids premium risks of top-tier high-end brands while eliminating quality hazards of low-end brands, helping overseas mid-to-high-end clients rapidly lock in matching products and efficiently access high-quality Chinese supply chains.
For inquiries regarding multi-brand and model comparative analysis, please contact HiSiaddi customer service.
+86-13120989737 
info@hisiaddi.com 
English
